BIVI (BioVie, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by BIVI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-28 | CUONG V DO | President & CEO | Buy | — | — |
| 2026-08-28 | JOANNE WENDY KIM | Chief Financial Officer | Buy | — | — |
| 2026-08-28 | Amy Suzon Chappell | Director | Buy | — | — |
| 2026-08-28 | Joseph M Palumbo | Chief Medical Officer | Buy | — | — |
| 2025-01-07 | CUONG V DO | President & CEO | A | — | — |
| 2025-01-07 | Robert J Hariri | Director | A | — | — |
| 2025-01-07 | Joseph M Palumbo | Chief Medical Officer | A | — | — |
| 2025-01-07 | JOANNE WENDY KIM | Chief Financial Officer | A | — | — |
| 2025-01-07 | RICHARD J BERMAN | Director | A | — | — |
| 2025-01-07 | SIGMUND ROGICH | Director | A | — | — |
| 2025-01-07 | James Paul Lang | Director | A | — | — |
| 2025-01-07 | Michael Edward Sherman | Director | A | — | — |
| 2024-07-12 | CUONG V DO | President & CEO | MIXED | — | — |
| 2024-07-12 | Joseph M Palumbo | Chief Medical Officer | MIXED | — | — |
| 2024-07-12 | JOANNE WENDY KIM | Chief Financial Officer | MIXED | — | — |
| 2024-03-06 | CUONG V DO | President & CEO | Buy | — | — |
| 2023-12-13 | JOANNE WENDY KIM | Chief Financial Officer | A | — | — |
| 2023-12-06 | Robert J Hariri | Director | A | — | — |
| 2023-12-06 | Michael Edward Sherman | Director | A | — | — |
| 2023-12-06 | RICHARD J BERMAN | Director | A | — | — |
| 2023-12-06 | STEVE GORLIN | Director | MIXED | — | — |
| 2023-12-06 | James Paul Lang | Director | A | — | — |
| 2023-12-06 | SIGMUND ROGICH | Director | A | — | — |
| 2023-12-01 | CUONG V DO | President & CEO | Buy | — | — |
| 2023-09-07 | STEVE GORLIN | Director | Sell | — | — |
| 2023-08-24 | RICHARD J BERMAN | Director | Sell | — | — |
| 2023-07-03 | JOANNE WENDY KIM | Chief Financial Officer | A | — | — |
| 2023-07-03 | Joseph M Palumbo | Chief Medical Officer | A | — | — |
| 2023-07-03 | CUONG V DO | CEO & President | A | — | — |
| 2023-06-26 | CUONG V DO | CEO & President | M | — | — |
| 2023-06-15 | RICHARD J BERMAN | Director | Sell | — | — |
| 2023-04-06 | RICHARD J BERMAN | Director | Sell | — | — |
| 2023-02-22 | Joseph M Palumbo | Chief Medical Officer | F | — | — |
| 2023-02-22 | JOANNE WENDY KIM | Chief Financial Officer | F | — | — |
| 2023-02-22 | CUONG V DO | CEO & President | F | — | — |
| 2023-02-22 | Clarence N. Ahlem | EVP Neuroscience Product Dev. | F | — | — |
| 2023-02-22 | CHRISTOPHER READING | EVP Neuroscience R&D | F | — | — |
| 2023-02-22 | PENELOPE MARKHAM | EVP Liver Cirrhosis R&D | F | — | — |
| 2023-01-18 | JOANNE WENDY KIM | Chief Financial Officer | A | — | — |
| 2023-01-18 | STEVE GORLIN | Director | A | — | — |
| 2023-01-18 | CHRISTOPHER READING | EVP Neuroscience R&D | A | — | — |
| 2023-01-18 | PENELOPE MARKHAM | EVP Liver Cirrhosis R&D | A | — | — |
| 2023-01-18 | SIGMUND ROGICH | Director | A | — | — |
| 2023-01-18 | James Paul Lang | Director | A | — | — |
| 2023-01-18 | Joseph M Palumbo | Chief Medical Officer | A | — | — |
| 2023-01-18 | CUONG V DO | CEO & President | A | — | — |
| 2023-01-18 | Michael Edward Sherman | Director | A | — | — |
| 2023-01-18 | RICHARD J BERMAN | Director | A | — | — |
| 2023-01-18 | Clarence N. Ahlem | EVP Neuroscience Product Dev. | A | — | — |
| 2023-01-18 | TERREN S PEIZER | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 127,701 | — |
| — | President & CEO | 21,636 | — |
| — | Chief Medical Officer | 6,036 | — |
| — | Director | 4,064 | — |
| — | Director | 3,693 | — |
| — | Chief Financial Officer | 3,441 | — |
| — | Director | 727 | — |
| — | Director | 715 | — |
| — | Director | 686 | — |
| — | EVP Liver Cirrhosis Programs | 486 | — |
| — | EVP Liver Cirrhosis R&D | 478 | — |
| — | Director | 423 | — |
| — | EVP Neuroscience R&D | 371 | — |
| — | EVP Neuroscience Product Dev. | 371 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BIVI quote page; the site-wide leaderboard is on the insider transactions hub.